According to a previous report by the BEGIN Basal-Bolus Type 1 Trial investigators [7], the mean doses of basal and premeal bolus insulin were significantly decreased by 14% and 10% in the insulin degludec group compared with the insulin glargine group at the end of the trial, leading to similar rate of overall hypoglycemia between insulin glargine and degludec groups. Here, INS is linked to Hypoglycemia.